文献速递鼻科

丙酸氟替卡松抑制SARS-CoV-2诱导的呼吸道上皮通透性增加:一项体外研究

Fluticasone propionate suppresses the SARS-CoV-2 induced increase in respiratory epithelial permeability in vitro.
PubMed 文献 · Rhinology · 2023-01-01

该研究采用Calu-3细胞和健康供者原代鼻上皮细胞的气液界面培养,探讨丙酸氟替卡松对SARS-CoV-2诱导的上皮屏障破坏、病毒复制及ACE2表达的预防作用。结果显示,丙酸氟替卡松预处理48小时可阻止SARS-CoV-2诱导的4 kDa异硫氰酸荧光素-葡聚糖通透性增加,减少SARS-CoV-2感染,并降低感染细胞中ACE2表达。

要点

  • 丙酸氟替卡松预处理48小时可阻止SARS-CoV-2诱导的上皮通透性增加。
  • 丙酸氟替卡松预处理可减少SARS-CoV-2感染并降低感染Calu-3细胞中ACE2表达。
  • 结果提示丙酸氟替卡松在COVID-19背景下的治疗潜力。

核心结论

  • 丙酸氟替卡松预处理可阻止SARS-CoV-2诱导的上皮通透性增加,降低ACE2表达并减少SARS-CoV-2感染,凸显其在COVID-19背景下的治疗潜力。

研究设计与样本

  • 体外研究,使用Calu-3细胞和健康供者原代鼻上皮细胞的气液界面培养。

主要发现

  • 丙酸氟替卡松预处理48小时可阻止SARS-CoV-2诱导的4 kDa异硫氰酸荧光素-葡聚糖通透性增加。
  • 丙酸氟替卡松预处理可减少SARS-CoV-2感染。
  • 丙酸氟替卡松预处理可降低SARS-CoV-2感染的Calu-3细胞中ACE2表达。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Disruption of the nasal epithelial barrier is believed to play a role in Coronavirus Disease-2019 (COVID-19) outcomes. Fluticasone propionate has been shown to restore the nasal epithelial barrier in allergic rhinitis to the level of healthy controls. The therapeutic potential of nasal steroid sprays in COVID-19 has recently been reported. However, further insight into the mode of action is warranted. OBJECTIVES: To explore the in vitro mechanisms of the preventive potential of fluticasone propionate in SARS-CoV-2 infection. METHODS: Human air liquid interface cultures of Calu-3 cells and primary nasal epithelial cells isolated from healthy donors were used to investigate the preventive effect of fluticasone propionate on SARS-CoV-2 induced barrier disruption, virus replication and ACE2 expression. RESULTS: 48 hours pre-treatment with fluticasone propionate prevented the SARS-CoV-2 induced increase in fluorescein isothiocyanate-dextran 4 kDa permeability and reduced infection with SARS-CoV-2. Pre-treatment with fluticasone propionate also decreased ACE2 expression in SARS-CoV-2 infected Calu-3 cells. CONCLUSION: Fluticasone propionate pre-treatment prevented SARS-CoV-2 increased epithelial permeability, reduced ACE2 expression and SARS-CoV-2 infection, underscoring the therapeutic potential of fluticasone propionate in the context of COVID-19.

来源:Rhinology,查看原文。版权归原作者所有。

引用

  1. Martens K, Vanhulle E, Viskens AS, et al. Fluticasone propionate suppresses the SARS-CoV-2 induced increase in respiratory epithelial permeability in vitro. Rhinology. 2023. PMID: 36479866. doi:10.4193/Rhin22.223

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。